CTI BioPharma (NASDAQ:CTIC) issued its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.04), Bloomberg Earnings reports. CTI BioPharma had a negative return on equity of 233.13% and a negative net margin of 161.74%. The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $1.00 million. During the same period in the previous year, the company earned ($0.70) earnings per share.
Shares of CTI BioPharma (NASDAQ CTIC) traded up $0.01 on Wednesday, reaching $4.05. The company had a trading volume of 220,895 shares, compared to its average volume of 674,992. CTI BioPharma has a twelve month low of $2.45 and a twelve month high of $4.65. The stock has a market cap of $234.83, a PE ratio of -3.93 and a beta of 0.04. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.44 and a quick ratio of 2.41.
In other news, major shareholder Bvf Partners L. P/Il acquired 5,634,108 shares of CTI BioPharma stock in a transaction dated Friday, February 9th. The shares were purchased at an average cost of $3.00 per share, for a total transaction of $16,902,324.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Value Fund L. P. Biotechnology acquired 6,333,333 shares of CTI BioPharma stock in a transaction dated Friday, February 9th. The shares were purchased at an average price of $3.00 per share, for a total transaction of $18,999,999.00. The disclosure for this purchase can be found here. Company insiders own 2.16% of the company’s stock.
CTI BioPharma Company Profile
CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.